Atypical radiographic changes seen in dogs treated with bedinvetmab (Librela).

Bedinvetmab may cause atypical periarticular bone remodeling detectable radiographically, warranting routine musculoskeletal monitoring.

This pharmacovigilance study describes atypical adverse musculoskeletal findings in dogs treated with bedinvetmab (Librela), a canine anti-NGF monoclonal antibody used for osteoarthritis pain management. Researchers reviewed the Zoetis Global Pharmacovigilance database from November 2020 through December 2025, identifying 319 potential adverse musculoskeletal event cases. Of these, 186 cases met inclusion criteria and demonstrated atypical radiographic findings that could not be attributed to normal osteoarthritis progression or other recognized orthopedic conditions. The most frequently observed change was abnormal periarticular bone remodeling, though additional significant radiographic changes were also identified. The elbow and tarsus were the most commonly affected joints. Radiographic changes were observed unilaterally and bilaterally, could be progressive over time, and could affect multiple joints within the same patient. Concurrent NSAID administration was reported in 63% of cases (118 dogs), and off-label bedinvetmab use was documented in 25% of cases (46 dogs). The authors emphasize that these findings represent a distinct clinical and radiographic pattern not typically associated with other musculoskeletal diseases, suggesting bedinvetmab may be causally linked to these changes, potentially related to NGF pathway inhibition affecting bone homeostasis. Clinicians are advised to be aware of these atypical radiographic changes when monitoring dogs on bedinvetmab therapy, particularly those receiving concurrent NSAIDs or being treated off-label.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.